Table 2.
Descriptive statistics for the 604 dogs with inflammatory disease affecting the brain.
|
MUO (n = 468) |
Other immune-mediated causes (n = 63) |
Infectious causes (n = 73) |
|
|---|---|---|---|
| Median age (IQR) | 48 months (51) | 27 months (39) | 58 months (61) |
| Median body weight (IQR) | 8 kg (7) | 9.9 kg (11.3) | 15.6 kg (17.8) |
| Sex | |||
| Female | 259 (55.4%) | 36 (57.1%) | 24 (32.9%) |
| Male | 209 (44.6%) | 27 (42.9%) | 49 (67.1%) |
| Neuter status | |||
| Intact | 183 (39.1%) | 22 (34.9%) | 31 (42.5%) |
| Neutered | 285 (60.9%) | 41 (65.1%) | 42 (57.5%) |
| Breed categories | |||
| Crossbreeds | 66 (14.2%) | 15 (23.8%) | 6 (8.2%) |
| Sporting | 48 (10.3%) | 8 (12.7%) | 19 (26%) |
| Hound | 8 (1.7%) | 17 (27%) | 8 (11%) |
| Working | 14 (3%) | 1 (1.6%) | 12 (16.5%) |
| Terrier | 95 (20.3%) | 13 (20.6%) | 5 (6.8%) |
| Toy | 185 (39.6%) | 7 (11.1%) | 12 (16.5%) |
| Herding | 7 (1.5%) | 1 (1.6%) | 2 (2.7%) |
| Non-sporting | 44 (9.4%) | 1(1.6%) | 9 (12.3%) |
| Previous similar episode | 31 (6.6%) | 1 (1.6%) | 9 (12.3%) |
| Possibly associated preceding event | 31 (6.6%) | 13 (20.6%) | 7 (9.6%) |
| Onset of clinical signs | |||
| Acute | 156 (33.4%) | 15 (23.8%) | 26 (35.6%) |
| Subacute | 110 (23.6%) | 17 (27%) | 14 (19.2%) |
| Chronic | 201 (43%) | 31 (49.2%) | 33 (45.2%) |
| Median duration of clinical signs (IQR) | 7 days (12) | 7 days (10) | 6 days (19) |
| Progression of clinical signs | 388 (82.9%) | 54 (85.7%) | 65 (89%) |
| Hyperthermia on presentation | 22 (4.7%) | 16 (25.4%) | 16 (22%) |
| Hyperesthesia on presentation | 152 (32.5%) | 10 (15.9%) | 27 (37%) |
| Median CSF TNCC (IQR) | 36 cells/μl (208) | 15 cells/μl (63) | 201 cells/μl (2,409) |
| Median CSF protein concentration (IQR) | 0.47 g/L (0.73) | 0.21 g/L (0.24) | 0.69 g/L (1.54) |
| Survival to discharge | 381 (81.4%) | 62 (98.4%) | 62 (84.9%) |
CSF, cerebrospinal fluid; IQR, interquartile range; MUO, meningoencephalomyelitis of unknown origin; TNCC, total nucleated cell count.